Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.

Multiple myeloma (MM) is characterized by excessive aggregation of B-cell-derived malignant plasma cells in the hematopoietic system of bone marrow. Previously, we synthesized an innovative molecule named dihydrocelastrol (DHCE) from celastrol, a triterpene purified from medicinal plant Tripterygium wilfordii. Herein, we explore the therapeutic properties and latent signal transduction mechanism of DHCE action in bortezomib (BTZ)-resistant (BTZ-R) MM cells. In this study, we first report that DHCE shows antitumor activities in vitro and in vivo and exerts stronger inhibitory effects than celastrol on BTZ-R cells. We find that DHCE inhibits BTZ-R cell viability by promoting apoptosis via extrinsic and intrinsic pathways and suppresses BTZ-R MM cell proliferation by inducing G0/G1 phase cell cycle arrest. In addition, inactivation of JAK2/STAT3 and PI3K/Akt pathways are involved in the DHCE-mediated antitumor effect. Simultaneously, DHCE acts synergistically with BTZ on BTZ-R cells. PSMB5, a molecular target of BTZ, is overexpressed in BTZ-R MM cells compared with BTZ-S MM cells and is demonstrated to be a target of STAT3. Moreover, DHCE downregulates PSMB5 overexpression in BTZ-R MM cells, which illustrates that DHCE overcomes BTZ resistance through increasing the sensitivity of BTZ in resistant MM via inhibiting STAT3-dependent PSMB5 regulation. Overall, our findings imply that DHCE may become a potential therapeutic option that warrants clinical evaluation for BTZ-R MM.

Heterodimensional superlattice with in-plane anomalous Hall effect.

Superlattices-a periodic stacking of two-dimensional layers of two or more materials-provide a versatile scheme for engineering materials with tailored properties1,2. Here we report an intrinsic heterodimensional superlattice consisting of alternating layers of two-dimensional vanadium disulfide (VS2) and a one-dimensional vanadium sulfide (VS) chain array, deposited directly by chemical vapour deposition. This unique superlattice features an unconventional 1T stacking with a monoclinic unit cell of VS2/VS layers identified by scanning transmission electron microscopy. An unexpected Hall effect, persisting up to 380 kelvin, is observed when the magnetic field is in-plane, a condition under which the Hall effect usually vanishes. The observation of this effect is supported by theoretical calculations, and can be attributed to an unconventional anomalous Hall effect owing to an out-of-plane Berry curvature induced by an in-plane magnetic field, which is related to the one-dimensional VS chain. Our work expands the conventional understanding of superlattices and will stimulate the synthesis of more extraordinary superstructures.

DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.

Diffuse large B cell lymphoma (DLBCL) is a clinical and genetically heterogeneous lymphoid malignancy. Although R-CHOP (rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment can improve the survival rate of patients with DLBCL, more than 30% of patients exhibit treatment failure, relapse, or refractory disease. Therefore, novel drugs or targeted therapies are needed to improve the survival of patients with DLBCL. The compound DCZ0014 is a novel chemical similar to berberine. In this study, we found that DCZ0014 significantly inhibited the proliferation and activity of DLBCL cells, and induced cell apoptosis. Following treatment with DCZ0014, DLBCL cells accumulated in G0/G1-phase of the cell cycle and showed decreased mitochondrial membrane potential. Additionally, DCZ0014 inhibited DNA synthesis, enhanced DNA damage in DLBCL cells, as well as inhibited Lyn/Syk in B cell receptor signaling pathway. Further experiments demonstrated that DCZ0014 did not significantly affect peripheral blood mononuclear cells. Tumor xenograft model showed that DCZ0014 not only inhibited tumor growth but also extended the survival time of mice. Thus, DCZ0014 showed potential for clinical application in the treatment of patients with DLBCL.

Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.

Mantle cell lymphoma (MCL) is a distinct and highly aggressive subtype of B-cell non-Hodgkin lymphoma. Dihydrocelastrol (DHCE) is a dihydro-analog of celastrol, which is isolated from the traditional Chinese medicinal plant Tripterygium wilfordii. The present study aimed to investigate the effects of DHCE treatment on MCL cells, and to determine the mechanism underlying its potent antitumor activity in vitro and in vivo using the Cell Counting kit-8 assay, clonogenic assay, apoptosis assay, cell cycle analysis, immunofluorescence staining, western blotting and tumor xenograft models. The results demonstrated that DHCE treatment exerted minimal cytotoxic effects on normal cells, but markedly suppressed MCL cell proliferation by inducing G0/G1 phase cell cycle arrest, and inhibited MCL cell viability by stimulating apoptosis via extrinsic and intrinsic pathways. In addition, the results revealed that DHCE suppressed cell growth and proliferation by inhibiting mammalian target of rapamycin complex (mTORC)1-mediated phosphorylation of ribosomal protein S6 kinase and eukaryotic initiation factor 4E binding protein. Simultaneously, DHCE induced apoptosis and inhibited cell survival by suppressing mTORC2-mediated phosphorylation of protein kinase B and nuclear factor-κB activity. In addition to in vitro findings, DHCE treatment reduced the MCL tumor burden in a xenograft mouse model, without indications of toxicity. Furthermore, combined treatment with DHCE and bortezomib, a proteasome inhibitor, induced a synergistic cytotoxic effect on MCL cells. These findings indicated that DHCE may have the potential to serve as a novel therapeutic agent for the treatment of MCL through dually inhibiting mTORC1 and mTORC2.

The Effects of Agave fourcroydes Powder as a Dietary Supplement on Growth Performance, Gut Morphology, Concentration of IgG, and Hematology Parameters in Broiler Rabbits.

This study was conducted to determine the effects of Agave fourcroydes powder as a dietary supplement on the growth performance, gut morphology, serum concentration of IgG, and the hematology parameters of broiler rabbits. A total of 32 rabbits [New Zealand × Californian] were weaned at 35 days. They were randomly selected for two dietary treatments (eight repetitions per treatment), which consisted of a basal diet and a basal diet supplemented with 1.5% dried-stem powder of A. fourcroydes. On day 60 from the initiation of treatment, gut histomorphology (duodenum and cecum), serum concentration of IgG, and hematology parameters were all measured. The results showed that A. fourcroydes powder supplementation improved (P < 0.05) the ADFI, ADG, and final BW. Correspondingly, this treatment increased (P < 0.05) the muscle and mucosa thickness and height and width of villi. However, duodenum crypts depth was lower (P < 0.05) when rabbits were fed with this natural product, compared with the basal diet treatment. Results also indicated that the A. fourcroydes powder increased (P < 0.05) the serum concentration of IgG but did not change the hematology parameters. This data indicates that A. fourcroydes powder, as a supplement, had beneficial effects on increasing the growth performance and serum concentration of IgG, as well as improving the gut morphology without affecting the hematology parameters in broiler rabbits.

Metabolomic analysis of amino acid metabolism in colitic rats supplemented with lactosucrose.

Intestinal inflammation causes metabolic disorders. The purpose of this study was to determine the effect of dietary supplementation with lactosucrose (LS) on the serum metabolome and intestinal luminal content of fatty acids in colitic rats. Colitis was induced in rats using trinitrobenzene sulfonic acid. Subsequently, rats received intragastric administration of either 250 mg LS/kg body weight or saline (the control group) every day for 5 weeks. Short-chain fatty acids in the intestinal lumen, blood profile, and metabolites in serum were measured, respectively, using gas chromatography, biochemistry analyzer, and nuclear magnetic resonance-based metabolomics combined with multivariate statistics. Metabolic effects of LS included: (1) decreases in concentrations of branched-chain amino acids (isoleucine and valine), alanine, citric acid, trimethylamine oxide and taurine, and the abundance of aspartate aminotransferase in serum; (2) increases in concentrations of glucose metabolites (including succinate) in serum; and (3) altered concentrations of butyrate in the cecal content and of butyrate and acetate in the colon content. The results indicate that LS supplementation to colitic rats affects whole-body metabolism of amino acids and release of aspartate aminotransferase and alkaline phosphatase from tissues into the blood circulation, and enhances the production of short-chain fatty acids in the intestinal lumen.

[Research on the analgesic effect and mechanism of bornyl acetate in volatile oil from amomum villosum].

OBJECTIVE: To study the analgesic effect and mechanism of bornyl acetate, the main ingredient of Amomum Villosum Volatile oil. METHODS: The analgesic effects were tested by pressing tail method. The I, and II phase pain were observed with the pain model caused by formalin test. Influence of naloxone antagonism test on analgesic effect of bornyl acetate. RESULTS: Bornyl acetate produced obvious analgesic effects on pain models induced by pressing tail. Bornyl acetate had inhibitory effect on I and II phase pain in formalin inducing pain model animals. Analgesic effect induced by Bornyl acetate wasn't significantly reduced by naloxone. CONCLUSION: Bornyl acetate shows analgesic effects. The analgesic site may locate in both central and peripheral nervous system. Its analgesic action way not be related to the opioid receptor.

[Studies on the analgesic and anti-inflammatory effect of bornyl acetate in volatile oil from Amomum villosum].

OBJECTIVE: To study analgesic and anti-inflammatory effects of bornyl acetate, the main ingredient of Amomum villosum volatile oil. METHODS: The analgesic effects were tested by hot-plate and writhing reaction method, the ear swelling caused by dimethylbenzene in mice. RESULTS: Bornyl acetate could restrain writhing reaction caused by acetic acid glacial, lighten the pain caused by hot-plate. It could also suppress ear swelling caused by dimethylbenzene in mice. CONCLUSION: Bornyl acetate shows analgesic and anti-inflammatory effects.

Observation on the therapeutic effect of Shu Feng Huo Luo Pian for treatment of osseous arthritis.

OBJECTIVE: To evaluate the therapeutic effect of Chinese patent drug Shu Feng Huo Luo Pian ([symbol: see text] Pill for Dispelling Wind and Activating Collaterals) for the treatment of osseous arthritis. METHOD: 50 cases of osseous arthritis were divided randomly into two groups, the Shu Feng Huo Luo Pian group (the experimental group), including 30 cases (aged 63.5 +/- 4 years), treated with 2 such pills, p.o., bid; and the control group, including 19 cases (aged 63 +/- 5 years), treated with Sulindac 0.2 g, p.o., bid. The two groups were all supplemented by medication of calcium Caltrate D 0.6 g, p.o., qd. The above-mentioned medications were administered for 2 courses, 2 weeks constituting a course. RESULT: The total effective rate of the experimental group evaluated by the doctors was 83.3%, and that evaluated by the patients was 90%, with mild side effects. CONCLUSION: Shu Feng Huo Luo Pian is an effective Chinese patent drug for treating osseous arthritis, with less and mild side effects.